Evoke Pharma Inc (NASDAQ:EVOK) shares rose 7.6% during trading on Thursday . The company traded as high as $1.34 and last traded at $1.27. Approximately 996,434 shares changed hands during trading, an increase of 327% from the average daily volume of 233,603 shares. The stock had previously closed at $1.18.

EVOK has been the subject of a number of analyst reports. B. Riley set a $5.00 price target on shares of Evoke Pharma and gave the stock a “buy” rating in a research note on Monday. HC Wainwright set a $9.00 price target on shares of Evoke Pharma and gave the stock a “buy” rating in a research note on Monday, December 10th. Finally, Zacks Investment Research upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Monday, December 3rd.

Evoke Pharma (NASDAQ:EVOK) last posted its earnings results on Wednesday, March 6th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). On average, equities research analysts anticipate that Evoke Pharma Inc will post -0.56 EPS for the current year.

Several large investors have recently bought and sold shares of EVOK. JPMorgan Chase & Co. bought a new position in shares of Evoke Pharma in the third quarter valued at approximately $111,000. Wambolt & Associates LLC bought a new position in shares of Evoke Pharma in the fourth quarter valued at approximately $82,000. Finally, BlackRock Inc. raised its stake in shares of Evoke Pharma by 5.5% in the fourth quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock valued at $207,000 after acquiring an additional 4,392 shares during the last quarter. Institutional investors own 18.37% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Evoke Pharma (EVOK) Stock Price Up 7.6%” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/evoke-pharma-evok-stock-price-up-7-6/2873607.html.

About Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Further Reading: Day Trading

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.